Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and Temozolomide in Advanced HCC
NCT01205828Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Aug 2010
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of veliparib in hepatocellular carcinoma (HCC), sponsored by Georgetown University. Primary endpoint: Clinical Benefit Rate at 8 weeks. Started Aug 2010; status: terminated.
02
Drugs
veliparib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01205828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01205828.